Introduction {#s1}
============

Through multiple rounds of selection and escape, host and pathogen genomes are imprinted with signatures of co-evolution that are governed by Darwinian forces. On the host side, well-characterized anti-retroviral restriction factors, such as *TRIM5α*, *APOBEC3G* and *BST2*, harbor strong signals of selection in primate genomes, clear examples of retroviral pressure ([@bib27]). On the virus side, obvious signs of selection are observable in the HIV-1 genome: escape mutations and reversions have been described in epitopes restricted by human leukocyte antigen (HLA) class I molecules and targeted by cytotoxic T lymphocyte (CTL) responses ([@bib16]; [@bib21]). Sequence polymorphisms have also been reported recently in regions targeted by killer immunoglobulin-like receptors (KIR), suggesting evasion from immune pressure by natural killer (NK) cells ([@bib3]). Evidence for the remodeling of retroviral genomes by host genetic pressure also comes from simian immunodeficiency virus (SIV) infection studies in rhesus macaques, where escape from restrictive *TRIM5α* alleles has been observed in the viral capsid upon cross-species transmission of SIVsm ([@bib22]). In contrast, human alleles of *TRIM5α* do not result in escape mutations, likely because of adaptation of the pathogen to the host ([@bib32]). Sequence adaptation is also a known feature of cross-species transmission. For example, a methionine in the matrix protein (Gag-30) in SIV~cpzPtt~ changed to arginine in lineages leading to HIV-1 and reverted to methionine when HIV-1 was passaged through chimpanzees ([@bib41]).

To date, combined analyses of human and HIV-1 genetic data have addressed the association of HLA and KIR genes with variants in the retroviral genome ([@bib26]; [@bib7]; [@bib4]; [@bib21]; [@bib3]; [@bib8]; [@bib42]). Additionally, genome-wide association studies (GWAS) performed in the host have focused on various HIV-related clinical phenotypes ([@bib15]; [@bib14]; [@bib28]). In parallel, large amounts of HIV-1 sequence data have been generated for phylogenetic studies, which shed new light on viral transmission and evolution ([@bib23]; [@bib1]; [@bib39]), or allow clinically driven analyses of viral genes targeted by antiretroviral drugs (resistance testing) ([@bib40]).

Building on the unprecedented possibility to acquire and combine paired human and viral genomic information from the same infected individuals; we employ an innovative strategy for global genome-to-genome host--pathogen analysis. By simultaneously testing for associations between genome-wide human variation, HIV-1 sequence diversity, and plasma viral load (VL), our approach allows the mapping of all sites of host--pathogen genomic interaction, the correction for both host and viral population stratification, and the assessment of the respective impact of human and HIV-1 variation on a clinical outcome ([Figure 1](#fig1){ref-type="fig"}).10.7554/eLife.01123.003Figure 1.A triangle of association testing.The following association analyses were performed: \[Study A\] human SNPs vs plasma viral load (1 GWAS); \[Study B\] human SNPs vs variable HIV-1 amino acids (3007 GWAS); and \[Study C\] variable HIV-1 amino acids vs plasma viral load (1 proteome-wide association study).**DOI:** [http://dx.doi.org/10.7554/eLife.01123.003](10.7554/eLife.01123.003)

Results {#s2}
=======

Study participants, host genotypes, and HIV-1 sequence variation {#s2-1}
----------------------------------------------------------------

Full-length HIV-1 genome sequence and human genome-wide SNP data were obtained from seven studies or institutions on a total of 1071 antiretroviral naive patients of Western European ancestry, infected with HIV-1 subtype B. The homogeneity of the study population was confirmed by principal component analysis of the genotype matrix: together, the first five principal components explained 1% of total genotypic variation. After quality control of the human genotype data, imputation and filtering, ∼7 million SNPs were available for association testing. The full-length HIV-1 sequence is approximately 9.5 Kb long, corresponding to over 3000 encoded amino acids. Not all sequences were complete; on an average, viral residues were covered in 85% of the study population (range: 75% in Tat to 95% in Gag). Due to its hypervariable nature, the portion of the HIV-1 envelope gene that encodes the gp120 protein was not sequenced in most study samples and was therefore excluded. Overall 1126 residues of the HIV-1 proteome were found to be variable in at least 10 samples, for a total of 3381 different viral amino acids that could be represented by 3007 distinct binary variables.

Host VL GWAS {#s2-2}
------------

We first performed a classical GWAS of host determinants of HIV-1 VL ([Figure 2A](#fig2){ref-type="fig"}, [Study A]{.ul}) using data from 698 patients (65% of the study population) for whom a VL phenotype could be reliably estimated. The top associations were observed in the HLA class I region on chromosome 6 and were highly consistent with results observed previously ([@bib14]; [@bib28]). The strongest associated SNP, rs9267454 (p = 1.5 × 10^−8^), is in partial linkage disequilibrium (LD) with HLA-B\*57:01 (r^2^ = 0.47, D′ = 0.92), HLA-B\*14:01 (r^2^ = 0.12, D′ = 1.0), HLA-B\*27:05 (r^2^ = 0.01, D′ = 0.99), and the HLA-C -35 rs9264942 SNP (r^2^ = 0.07, D′ = 0.77), and thus reflects these well-known associations with HIV-1 control. These results confirm the quality of the study population for the purpose of genome analysis of determinants of HIV-1-related outcomes.10.7554/eLife.01123.004Figure 2.Results of the genome-wide association analyses.(**A**) Associations between human SNPs and HIV-1 plasma viral load. The dotted line shows the Bonferroni-corrected significance threshold (p-value \< 7.25 × 10^−9^). (**B**) Associations between human SNPs and HIV-1 amino acid variants, with 3007 GWAS collapsed in a single Manhattan plot. The dotted line shows the Bonferroni-corrected significance threshold (p-value \< 2.4 × 10^−12^). (**C**) Schematic representation of the HLA class I genes and of the SNPs associated with HIV-1 amino acid variants in the region. (**D**) Same association results as in panel **B**, projected on the HIV-1 proteome. Only the strongest association is shown for each amino acid. Significant associations are indicated by a blue dot. The gp120 part of the HIV-1 proteome was not tested. The colored bar below the plot area shows the positions of the optimally defined CD8+ T cell epitopes. An interactive version of this figure can be found at [http://g2g.labtelenti.org](http://g2g.labtelenti.org/) (which is also available to download from Zenodo, <http://dx.doi.org/10.5281/zenodo.7138>).**DOI:** [http://dx.doi.org/10.7554/eLife.01123.004](10.7554/eLife.01123.004)

Genome-to-genome analyses {#s2-3}
-------------------------

3007 genome-wide analyses of associations between human SNPs and HIV-1 amino acid variants were performed in the full sample of 1071 individuals ([Figure 2B](#fig2){ref-type="fig"}, [Study B]{.ul}) using logistic regression corrected for viral phylogeny ([@bib9]; [@bib8]). Highly significant associations were observed between SNPs in the major histocompatibility complex (MHC) region and multiple amino acids throughout the HIV-1 proteome (except in Vpu, Rev and the RNaseH subunit of RT) ([Figure 2C](#fig2){ref-type="fig"}), with Gag and Nef having a significantly higher density of associated variable sites than the rest of the proteome (Gag: 6.8% vs 2.6% p=0.001; Nef: 11% vs 2.6% p = 1.2 × 10^−5^, binomial tests). Using Bonferroni correction for multiple testing (threshold p = 2.4 × 10^−12^), significant human SNP associations were observed with 48 viral amino acids ([Figure 2](#fig2){ref-type="fig"} and [Table 1](#tbl1){ref-type="table"}). None of these 48 amino acids mapped to known sites of major antiretroviral drug resistance mutations ([@bib17]). The strongest association found was between rs72845950 and Nef position 135 (p = 2.7 × 10^−66^). Associations were much stronger between human SNPs and HIV-1 amino acids than with VL. For example, the SNP rs2395029, a proxy for HLA-B\*57:01 (r^2^ = 0.93), has a p-value of 1.21 × 10^−6^ for association with VL, while it reaches a p-value of 4 × 10^−59^ for association with amino acid variation in Gag at position 242 (a well known position of escape from HLA-B\*57:01). No significant signals were identified outside the MHC. A link to the complete set of association results can be found at [http://g2g.labtelenti.org](http://g2g.labtelenti.org/) (which is also available to download from Zenodo, <http://dx.doi.org/10.5281/zenodo.7139>). These results demonstrate the feasibility and improved power of performing association testing using viral genetic variation as outcome, independent of clinical phenotype.10.7554/eLife.01123.005Table 1.Associations between HIV-1 amino acid variants and human polymorphisms**DOI:** [http://dx.doi.org/10.7554/eLife.01123.005](10.7554/eLife.01123.005)HIV geneHIV positionSNPCTL epitope (codons)Tagging HLA (D'/r^2^)SNP vs aa (p)SNP vs VL (p)aa vs VL (p)GAG12chr6:31285512--B\*49:01 (1.00/1.00)2.20E-136.70E-015.60E-01GAG26rs12524487--B\*15:01 (1.00/0.82)6.10E-192.10E-011.40E-01GAG28rs1655912RLRPGGKKK (20--28)A\*03:01 (1.00/0.81)2.70E-555.60E-012.00E-02GAG79chr6:31267544LYNTVATL (78-85)C\*14:02 (1.00/0.96)2.40E-123.50E-012.80E-01GAG147rs1055821--C\*06:02 (0.95/0.71)3.10E-173.30E-072.90E-05GAG242rs73392116TSTLQEQIGW (240--249)B\*57:01 (1.00/0.98)2.40E-621.90E-061.70E-05GAG248rs41557213TSTLQEQIGW (240-249)B\*57:01 (1.00/0.97)4.80E-152.00E-065.30E-03GAG264chr6:31376564KRWIILGLNK (263--272)B\*27:05 (1.00/0.92)2.30E-135.50E-023.50E-01GAG268rs2249935GEIYKRWIIL (259--268)B\*08:01 (1.00/0.43)2.20E-145.10E-011.90E-01GAG340rs11966319--B\*15:01 (0.94/0.42)6.70E-144.60E-017.70E-01--C\*03:04 (0.99/0.59)GAG357rs2523612GPGHKARVL (355-363)B\*07:02 (0.99/0.95)2.70E-192.20E-011.20E-01--C\*07:02 (0.99/0.84)GAG397rs61754472--A\*31:01 (0.97/0.83)8.80E-213.50E-018.30E-01GAG403rs28896571----8.90E-217.90E-018.60E-01GAG437rs34268928RQANFLGKI (429-437)B\*13:02 (1.00/0.96)8.70E-141.80E-026.80E-02GP41206rs17881210--B\*15:01 (1.00/0.88)6.10E-176.10E-013.00E-01GP41267rs9278477RLRDLLLIVTR (259--269)A\*03:01 (1.00/0.01)1.00E-127.80E-012.60E-01INT11rs2596477--B\*44:02 (1.00/0.64)5.10E-331.50E-011.80E-01INT32rs1050502--B\*51:01 (0.97/0.92)4.80E-187.20E-014.00E-01INT119rs9264954--C\*05:01 (1.00/1.00)1.30E-247.90E-011.10E-01INT122rs9264419--C\*05:01 (1.00/0.95)4.50E-228.30E-017.80E-01INT124chr6:31345421STTVKAACWW (123--132)B\*57:01 (1.00/1.00)3.00E-131.10E-069.70E-03NEF71rs2596488FPVTPQVPLR (68--77)B\*07:02 (1.00/0.98)3.80E-552.50E-018.10E-02--C\*07:02 (0.95/0.83)NEF81rs9295987RPMTYKAAL (77--85)B\*07:02 (1.00/0.01)4.80E-362.50E-019.50E-02--C\*04:01 (0.90/0.63)NEF83rs34768512--B\*15:01 (1.00/0.47)2.20E-172.80E-011.50E-02--C\*03:04 (0.96/0.54)NEF85rs2395475RPMTYKAAL (77--85)B\*07:02 (1.00/0.29)1.90E-248.10E-011.30E-03--B\*08:01 (1.00/0.22)--C\*07:02 (0.97/0.30)NEF92rs16896166AVDLSHFLK (84--92)A\*11:01 (1.00/0.99)1.00E-275.30E-011.50E-01NEF94rs9265972FLKEKGGL (90--97)B\*08:01 (1.00/0.97)9.60E-359.80E-011.20E-01NEF102rs2524277--B\*44:03 (0.98/0.96)1.10E-134.40E-012.40E-01NEF105rs1049709--C\*07:01 (1.00/0.98)1.10E-359.00E-012.70E-01NEF116chr6:31402358HTQGYFPDW (116--124)B\*57:01 (1.00/1.00)3.00E-221.90E-063.30E-01NEF120chr6:31236168-C\*14:02 (1.00/1.00)4.40E-163.60E-011.20E-02NEF126chr6:31102273--B\*51:01 (1.00/0.18)1.10E-121.80E-014.90E-02NEF133chr6:31397689--B\*35:01 (0.95/0.89)2.80E-192.50E-013.40E-01NEF135rs72845950RYPLTFGW (134--141)A\*24:02 (1.00/0.88)2.70E-669.10E-025.50E-03PR35rs2523577EEMNLPGRW (34-42)B\*44:02 (1.00/0.64)1.70E-181.60E-015.70E-01PR93rs2263323--B\*15:01 (0.98/0.92)5.60E-304.70E-019.50E-01RNASE28rs2428481--B\*08:01 (1.00/1.00)1.80E-128.10E-016.20E-01RT135rs1050502TAFTIPSI (128--135)B\*51:01 (0.97/0.92)6.70E-457.20E-013.00E-01RT245chr6:31411714IVLPEKDSW (244--252)B\*57:01 (1.00/0.98)2.90E-211.20E-065.40E-02RT277rs3128902QIYPGIKVR (269--277)A\*03:01 (1.00/0.99)1.20E-658.20E-012.70E-01RT369rs17190134--B\*13:02 (0.93/0.86)3.50E-206.40E-021.40E-01RT395rs17194293---1.50E-121.20E-017.70E-02TAT29rs9260615--A\*32:01 (0.98/0.95)4.40E-143.90E-011.40E-01TAT32rs16899214CCFHCQVC (30--37)C\*12:03 (0.98/0.96)6.40E-213.40E-014.90E-01VIF33chr6:31430060ISKKAKGWF (31--39)B\*57:01 (1.00/0.98)1.50E-139.90E-079.30E-03VIF51rs7767850--B\*49:01 (1.00/1.00)1.40E-125.20E-012.10E-01VIF74rs2395029--B\*57:01 (1.00/0.98)5.40E-139.70E-072.80E-01VPR32chr6:31362941VRHFPRIWL (31--39)B\*27:05 (1.00/0.94)3.10E-135.40E-026.50E-01[^3]

SNPs, HLA alleles and CTL epitopes {#s2-4}
----------------------------------

We next assessed whether the top SNPs associated with HIV-1 amino acids represent indirect markers of HLA class I alleles known to exert evolutionary pressure on HIV-1 ([Table 1](#tbl1){ref-type="table"}). We tested pairwise correlations between significant MHC SNPs and HLA class I alleles. The analysis confirmed the existence of high LD between SNPs and HLA alleles targeting corresponding epitopes. For example, the strongest association (p = 2.7 × 10^−66^) was observed between residue 135 in Nef, located in an optimally defined A\*24:02 epitope, and rs72845950, which strongly tags HLA-A\*24:02 (r^2^ = 0.89). Furthermore, we observed that a substantial fraction of the identified viral amino acids (24/48, 50%) were located within an optimally defined CTL epitope restricted by one or more HLA alleles tagged by the associated SNP (<http://www.hiv.lanl.gov/content/immunology/tables/optimal_ctl_summary.html>, supplemented with a recently updated list of epitopes \[[@bib8]\]). However, in seven cases, the classical HLA allele implicated through LD with a tagging SNP did not match previously reported restriction patterns ([Table 1](#tbl1){ref-type="table"}). These data demonstrate that this approach can reconstruct a map of targets of HLA pressure across the viral proteome and identify sites outside classical epitopes that could represent additional escape variants or compensatory mutations. That a substantial proportion of associated viral amino acids lay outside known CTL epitopes also highlights this approach as a tool to guide novel epitope discovery ([@bib4]; [@bib2]).

Analysis of polymorphic amino acids within the HLA genes has been shown to improve power for detection of association with clinical outcome and has demonstrated the biological relevance of key residues in the HLA-B binding groove ([@bib28]). Therefore, we used the genome-to-genome framework to characterize the evolutionary pressure of HLA class I amino acids on the viral genome. The top associations in all classical class I genes mapped to discrete residues in the binding grooves of the HLA molecule: HLA-A position 62 (p = 3.3 × 10^−76^ with HIV Nef 135), HLA-B position 70 (p = 7.1 × 10^−57^ with HIV Gag 242), HLA-C position 99 (p = 5.4 × 10^−63^ with HIV Nef 70). These data indicate that all class I HLA genes can exert strong pressure on the viral proteome through a shared mechanism. The association results for HLA amino acids can also be found at [http://g2g.labtelenti.org](http://g2g.labtelenti.org/) (which is also available to download from Zenodo).

HIV-1 amino acids vs plasma viral load {#s2-5}
--------------------------------------

To address whether there was an observable impact of viral mutation on a clinical outcome in this sample, we tested for associations between all HIV-1 amino acid variant and VL (Study C). After correction for multiple testing (p threshold = 1.6 × 10^−5^ based on 3125 viral amino acids), we did not observe any significant associations. We then focused on estimating the changes in VL associated with the 48 HIV-1 amino acid variants that were identified as significantly associated with host SNPs ([Figure 2D](#fig2){ref-type="fig"}). The effects of amino acid variation at these sites on VL ranged from --0.16 to +0.07 log~10~ copies/ml ([Figure 3A](#fig3){ref-type="fig"}). We also explored the combined fitness effect of multiple HIV-1 viral amino acid variants targeted by a single host marker using the well-understood model of HLA-B\*57:01. We evaluated the effect on VL of 23 viral residues that associated with host variant rs2395029 (r^2^ = 0.93 with HLA-B\*57:01) in the genome-to-genome analysis (selection cutoff: p\<0.001). The marker rs2395029 was associated with a 0.38 log decrease in viral RNA copies/ml. The univariate effect on VL for each of the 23 viral amino acids targeted by this allele ranged from --0.16 to +0.12 ([Figure 3B](#fig3){ref-type="fig"}). These results suggest that the genome-to-genome approach can be linked to clinical/laboratory phenotypes, allowing for detailed understanding of the distribution and relative contribution of sites of host--pathogen interaction to disease outcome.10.7554/eLife.01123.006Figure 3.Association of HIV-1 amino acid variants with plasma viral load.(A) Changes in VL (slope coefficients from the univariate regression model and standard error, log~10~ copies/ml) for the 48 HIV-1 amino acids that are associated with host SNPs in the genome-to-genome analysis. (**B**) rs2395029, a marker of HLA-B\*57:01 is associated with a 0.38 log~10~ copies/ml lower VL (black bar) in comparison to the population mean. Gray bars represent changes in VL for amino acid variants associated with rs2395029 (p\<0.001). In case of multiallelic positions, the change in VL is shown for all minor amino acids combined vs the major amino acid (e.g., GAG147 not I).**DOI:** [http://dx.doi.org/10.7554/eLife.01123.006](10.7554/eLife.01123.006)

Discussion {#s3}
==========

HIV-1 host genomic studies performed so far have focused on clinically defined outcomes (resistance to infection, clinical presentation, disease progression or death) or on pathogen-related laboratory results (such as CD4+ T cell counts and VL set point). While useful, these phenotypes have significant drawbacks. First, consistency of phenotypic determination can be hard to achieve, and such inconsistency can adversely affect power in large-scale genetic studies performed across multiple centers ([@bib13]). Second, a relatively long follow-up in the absence of antiretroviral treatment is necessary to obtain informative data about the natural history of infection. However, international guidelines now propose an early start of antiretroviral therapy in most HIV-1 infected individuals ([@bib38]), making the collection of large numbers of long-term untreated patients not only unrealistic but also ethically questionable.

To overcome these limitations, we developed a novel approach for host genetic studies of infectious diseases, built on the unprecedented possibility to obtain paired genome-wide information from hosts and pathogens. We combined human polymorphism and HIV-1 sequence diversity in the same analytical framework to search for sites of human-virus genomic conflict, effectively using variation in HIV-1 amino acids as an 'intermediate phenotype' for association studies. Intermediate phenotypes have recently been shown to be useful in uncovering association signals that are not detectable using more complex clinical endpoints: illustrative examples include metabolomic biomarkers in cardiovascular research ([@bib36]), serum IgE concentration in the study of asthma ([@bib25]), or neuroimaging-based phenotypes in psychiatry genetics ([@bib33]). Variation in the pathogen sequence is an as-yet-untapped intermediate phenotype, specific by nature to genomic research in infectious diseases. Importantly, it depends on sequencing the pathogen, which could prove in many cases easier and more standardized than obtaining detailed clinical phenotypes.

Our approach allowed the mapping of host genetic pressure on the HIV-1 genome. The strongest association signals genome-wide were observed between human SNPs tagging HLA class I alleles and viral mutations in their corresponding CTL epitopes. Additional association signals were observed outside of optimally defined CTL epitopes, which could indicate novel epitopes, or represent secondary (compensatory) mutations. In a single experiment, these results recapitulate extensive epidemiological and immunogenetic research and represent a proof-of-concept that biologically meaningful association signals are identifiable using a hypothesis-free strategy. Indeed, host factors leading to viral adaptation can be uncovered by searching for associated imprints in the viral genome. Of note, the International HIV Controllers Study demonstrated the importance of specific amino acid positions in the HLA-B binding groove on a clinical outcome (elite control) ([@bib28])*.* We here extend this observation to the HLA-A and C grooves, emphasizing the similarity in mechanism of host pressure on the viral proteome that is not necessarily translated into observable clinical outcomes.

We found a higher density of amino acid positions under selection in Gag and Nef compared with the rest of the HIV proteome. This is consistent with earlier findings that indicate the importance of Gag p24-specific CTL responses in slower progression to AIDS ([@bib5]; [@bib6]) or controller status ([@bib12]). Moreover, this further demonstrates that mapping host pressure on the pathogen proteome can reveal biologically relevant effects.

Analyses were performed using samples from clinically well-characterized patients, most of them with repeated and reliable HIV-1 VL measurements in the absence of antiretroviral therapy. We were thus able to compare the results of GWAS assessing human genetic determinants of mean VL, a standard clinical correlate of HIV-1 control, and genome-to-genome GWAS on amino acid variants in the viral proteome. The use of HIV-1 variation as outcome resulted in a considerable gain in power to detect host factors: the lowest p-values were observed for SNPs mapping to the HLA class I region in both approaches, but associations were much stronger with HIV-1 amino acid variation than for HIV-1 VL (2.7 × 10^−66^ vs 1 × 10^−08^), even when accounting for the increased number of multiple tests.

In addition to identifying sites of interaction between the host and the pathogen, the study design allowed the scoring of biological consequences of such interaction, by assessing associations between host-driven escape at viral sites and an in vivo phenotype (VL). For example, we decomposed the effect of rs2395029 (a marker of HLA-B\*57:01) on VL to the effects of the multiple viral amino acid variants that are associated with that SNP. While some HIV-1 amino acid changes individually associate with decrease in VL, the compound image that emerges is one of a multiplicity of modest effects distributed across many residues. Correlations between host-associated variants and VL are difficult to interpret, because they may reflect fitness costs or compensation, the existence of strong ([@bib18]; [@bib8]) or novel ([@bib2]) immune responses, or the indirect impact of specific HLA class I alleles. Nevertheless, the observation that the majority of host-associated HIV-1 mutations do not correlate with any detectable change in VL confirms HIV's remarkable capacity to adapt and compensate to immune pressure, often without measurable fitness cost.

A significant confounder in both human and viral genomic analyses is the existence of population stratification, where shared ancestry between infected individuals, stratification by ethnic groups, non-random distribution of HIV-1 subtypes, or clusters of viral transmission can all have an influence on the population frequencies of specific mutations, and thus create spurious associations if not carefully controlled for. Previous studies usually controlled for viral population substructure but were limited in the control of human population stratification ([@bib26]; [@bib4]). Our approach offers the opportunity to correct for both factors, thanks to the availability of extensive host and viral genomic information.

The present sample size provided approximately 80% power to detect a common human variant (minor allele frequency of 10%) with an odds ratio of 4.2 in the genome-to-genome analysis (Study B) and a viral amino acid explaining approximately 4% of the variation in plasma viral load (Study C) at the respective significance thresholds ([@bib30]). Consistent with most studies performed in HIV-1 host genetics over the past few years (reviewed in [@bib37]), we did not identify previously unknown host genetic loci involved in host-viral interaction and HIV-1 restriction. The proposed approach can only detect polymorphic host factors that leave an imprint on the virus, which may exclude mediators of immunopathogenesis or genes involved in the establishment of tolerance ([@bib24]). An additional limitation is the incomplete nature of genomic information available both on the host side (common genotypes from GWAS) and on the viral side (near full-length consensus sequence; gp120 was not included in the analyses). Finally, the multiple hypothesis burden of a genome-to-genome scan is extremely high. It is conceivable that larger studies, or studies that focus on a subgroup of predefined host genes, would have power to detect novel associations. A comprehensive, but computationally challenging description of host--pathogen genomic interactions would require human genome sequencing, coupled with deep sequencing of intra-host retroviral subpopulations.

In summary, we used a genome-to-genome, hypothesis-free approach to identify associations between host polymorphisms and HIV-1 genomic variation. This strategy allows a global assessment of host--pathogen interactions at the genome level and reveals sites of genomic conflict. Comparable approaches are immediately applicable to explore other important infectious diseases, as long as polymorphic host factors exert sufficient selective pressure to trigger escape mutations in the pathogen. The observation that pathogen sequence variation, used as an intermediate phenotype, is more powerful than clinical and laboratory outcomes to identify some host factors allows smaller-scale studies and encourages analyses of less prevalent infectious diseases. Researchers involved in pathogen genome studies and host genetic studies should strongly consider the gathering of paired host--pathogen data.

Materials and methods {#s4}
=====================

Ethics statement {#s4-1}
----------------

Participating centers provided local Institutional Review Board approval for genetic analysis. Study participants provided informed consent for genetic testing, with the exception of a subset where a procedure approved by the relevant Research Ethics Board allowed the use of anonymized historical specimens in the absence of a specific informed consent.

Participants {#s4-2}
------------

Study participants are treatment-naïve individuals followed in one of the following cohorts or institutions: the Swiss HIV Cohort Study (SHCS, [www.shcs.ch](http://www.shcs.ch), \[[@bib35]\]); the HAART Observational Medical Evaluation and Research (HOMER) study in Vancouver, Canada ([www.cfenet.ubc.ca/our-work/initiatives/homer](http://www.cfenet.ubc.ca/our-work/initiatives/homer)); the AIDS Clinical Trials Group (ACTG) Network in the USA ([actgnetwork.org](http://actgnetwork.org)); the International HIV Controllers Study in Boston, USA (IHCS, [www.hivcontrollers.org](http://www.hivcontrollers.org)); Western Australian HIV Cohort Study, Perth, Australia; the AIDS Research Institute IrsiCaixa in Badalona, Spain; and the Instituto de Salud Carlos III in Madrid, Spain. To reduce noise due to host and viral diversity, we only included individuals of recent Western European ancestry (confirmed by clustering with HapMap CEU individuals in principal component analysis of the genotype data \[[@bib29]\]), and infected with HIV-1 subtype B (as assessed by the REGA Subtyping Tool \[[@bib11]\]). Plasma VL determinations in the absence of antiretroviral therapy were available from patients from the SHCS and the HOMER study. The VL phenotype was defined as the average of the log~10~-transformed numbers of HIV-1 RNA copies per ml of plasma, excluding measurements obtained in the first 6 months after seroconversion and during advanced immunosuppression (i.e., with \<100 CD4+ T cells per ml of blood). Consequently, 698 study participants were eligible for VL analysis.

Human genotype data {#s4-3}
-------------------

DNA samples were genotyped in the context of previous GWAS ([@bib14]; [@bib28]) or for the current study on various platforms, including the HumanHap550, Human 660W-Quad, Human1M and HumanOmniExpress BeadChips (Illumina Inc., San Diego, CA, USA), as well as the Genome-Wide Human SNP Array 6.0 (Affymetrix Inc., Santa Clara, CA, USA) ([Table 2](#tbl2){ref-type="table"}). Study participants were filtered on the basis of genotyping quality, a sex check, and cryptic relatedness. SNP quality control was performed separately for each dataset: SNPs were filtered on the basis of missingness (excluded if called in \<99% of participants), minor allele frequency (excluded if \<0.01), and marked deviation from Hardy-Weinberg equilibrium (excluded if p\<0.00005). Missing genotype imputation was performed with the Mach software per genotyping platform (in separate batches for Illumina 1M, OmniExpress, 550K and Affymetrix data) using 1000 Genomes Phase I CEU population data as reference haplotypes. Imputed markers were filtered on minor allele frequency (excluded if \<0.01) and imputation quality using Mach's reported r-squared measure (excluded if \<0.3). SNPs with a deviation in the allele frequencies between platforms were excluded. High-resolution HLA class I typing (4 digits; HLA-A, HLA-B, and HLA-C) was obtained using sequence-based methods, or imputed from the SNP genotyping data as described elsewhere ([@bib19]).10.7554/eLife.01123.007Table 2.Distribution of samples across genotyping platforms and cohorts**DOI:** [http://dx.doi.org/10.7554/eLife.01123.007](10.7554/eLife.01123.007)NGenotyping platformCohort140Illumina 1MACTG6Illumina OmniExpress 12v1HCARLOS III518Affymetrix 6.0HOMER136Illumina OmniExpress12v1HHOMER47Illumina 650kIHCS6Illumina 660W-QuadIRSICAIXA2Illumina 1MSHCS79Illumina 550kSHCS122Illumina OmniExpress12v1HSHCS15Illumina 550kWAHCS[^4]

HIV-1 sequence data {#s4-4}
-------------------

Near full-length retroviral sequence data were obtained by bulk sequencing of viral RNA present in pretreatment-stored plasma, and in 11 cases, of proviral DNA isolated from peripheral blood mononuclear cells, as previously described ([@bib34]; [@bib20]). We defined an amino acid residue as variable if at least 10 study samples presented an alternative allele. Per position, separate binary variables were generated for each alternate amino acid, indicating the presence or absence of that allele in a given sample.

Association analyses {#s4-5}
--------------------

To globally assess the association between human genomic variation (SNPs), HIV-1 proteomic variation (amino acids) and clinical outcome (VL), we performed three series of analyses ([Figure 1](#fig1){ref-type="fig"}): \[A\] human SNPs vs VL; \[B\] human SNPs vs HIV-1 amino acids; and \[C\] HIV-1 amino acids vs VL. To test for association between human SNPs and HIV-1 amino acids, we used phylogenetically corrected logistic regression ([@bib9]; [@bib10]). For association testing between polymorphic amino acids in human HLA genes and HIV sequence variation, we used standard logistic regression (for a binary HLA amino acid) or a multivariate omnibus test (when more than one alternate allele was present) including sex, cohort, and the coordinates of the first two principal component axes as covariates. We used linear regression models in PLINK to test for association between human SNPs and VL, and between HIV-1 amino acids and VL ([@bib31]), including sex, cohort, and the coordinates of the first two principal component axes as covariates ([@bib29]). An additive genetic model was used for all analyses involving human SNPs. Significance was assessed using Bonferroni correction (significance thresholds of 7.25 × 10^−9^, 2.4 × 10^−12^, and 1.6 × 10^−5^ for analyses A, B, and C, respectively, [Figure 1](#fig1){ref-type="fig"}).
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eLife posts the editorial decision letter and author response on a selection of the published articles (subject to the approval of the authors). An edited version of the letter sent to the authors after peer review is shown, indicating the substantive concerns or comments; minor concerns are not usually shown. Reviewers have the opportunity to discuss the decision before the letter is sent (see [review process](http://elife.elifesciences.org/review-process)). Similarly, the author response typically shows only responses to the major concerns raised by the reviewers.

Thank you for sending your work entitled "A genome-to-genome analysis of associations between human genetic variation, HIV-1 sequence diversity, and viral control" for consideration at *eLife*. Your article has been favorably evaluated by a Senior editor, a Reviewing editor, and 3 reviewers.

The Reviewing editor and the reviewers discussed their comments before we reached this decision, and the Reviewing editor has assembled the following comments to help you prepare a revised submission.

The study represents an important and novel direction in the analysis of host-pathogen interactions, namely the joint analysis of both host and pathogen genomes. With additional information on pathogen phenotype (viral load) this enables the authors to provide a detailed dissection of how genetic variation within the players influences outcome.

Overall, we felt the study was well designed and analysed. Although there are perhaps no great surprises in terms of findings, the finding of many associated viral variants outside epitopes and the stronger association between human variation and HIV variation, compared to viral load, are both interesting results. When revising, we would like you to focus on the following issues:

1\) The authors wish to include a clinical correlate in the study, and we understand the use of viral load as it is easy to measure and is associated with progression. However, viral load is not only the only marker of disease progression -- CD4 count, rate of CD4 decline, immune activation, time to starting therapy from seroconversion etc, so it is clear that clinical progression is multifactorial. (It is also widely reported that CD8 immune responses, especially ELISpots, do not associate with viral load). With this in mind, the authors can only conclude that when using viral load as the surrogate their method produces stronger P values, but it cannot be stated that their 'intermediate phenotype' can replace possible other clinical correlates.

2\) The authors have used sequences from proviral DNA and plasma DNA in the same analysis, without mentioning this apart from in the Methods. Whereas proviral DNA may represent a record of HLA-imposed selection pressure it may not represent the circulating virus, and therefore associations with viral load etc. may be misleading. One would expect to see some justification of this approach.

3\) It would help frame the findings better if the power of the association studies was given. How big an effect size were the studies powered to detect? Given the finding of Alizon et al. cited here and other related papers, are we to be surprised by the lack of associations in the viral proteome to VL study? Does this place an upper bound for effect size of associations? Similarly for the lack of associations outside of MHC, which seem quite definitive especially in the case of the host genome to viral genome study.

4\) The GWAS to viral sequence variation is probably the most interesting finding of this study, with 48 viral amino acids showing significant associations with host SNPs in the MHC. The strongest association is observed for position 135/Nef within an A\*24:04 restricted epitope and for a SNP which is known to tag A\*24:02. Assuming that this effect has a structural basis (i.e., the molecular interaction between peptide and MHC), why only show amino acids in the viral genome? Why not make it more "symmetric" and also look at the individual amino acids in the HLA molecules? Because the authors have imputed amino acid polymorphisms of the HLA proteins (Jia et al.), this should be relatively easy and potentially interesting.
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Author response

*1) The authors wish to include a clinical correlate in the study, and we understand the use of viral load as it is easy to measure and is associated with progression. However, viral load is not only the only marker of disease progression -- CD4 count, rate of CD4 decline, immune activation, time to starting therapy from seroconversion etc., so it is clear that clinical progression is multifactorial. (It is also widely reported that CD8 immune responses, especially ELISpots, do not associate with viral load). With this in mind, the authors can only conclude that when using viral load as the surrogate their method produces stronger P values, but it cannot be stated that their 'intermediate phenotype' can replace possible other clinical correlates*.

We fully agree that plasma viral load is one clinical variable associated with progression, but that it does not capture all aspects of clinical disease. We have modified the Abstract and the main text accordingly to correctly convey the message that the improvement in power refers to our greater capacity to detect host factors relevant to viral biology.

*2) The authors have used sequences from proviral DNA and plasma DNA in the same analysis, without mentioning this apart from in the Methods. Whereas proviral DNA may represent a record of HLA-imposed selection pressure it may not represent the circulating virus, and therefore associations with viral load etc. may be misleading. One would expect to see some justification of this approach*.

HIV-1 sequences were generated from proviral DNA in a very small number of study participants (N=11). In addition, there is no clear evidence that proviral DNA is less likely to reflect intra-host host pressure. While it has been shown that escape mutations in proviral DNA can lag a few months vs the circulating virus, in this cross-sectional study of chronically infected subjects most escape mutations should already have occurred and any minor delays in escape rates would not be expected to effect the results given the stability of viral loads during chronic infection.

*3) It would help frame the findings better if the power of the association studies was given. How big an effect size were the studies powered to detect? Given the finding of Alizon et al. cited here and other related papers, are we to be surprised by the lack of associations in the viral proteome to VL study? Does this place an upper bound for effect size of associations? Similarly for the lack of associations outside of MHC, which seem quite definitive especially in the case of the host genome to viral genome study*.

We agree with the reviewers that power calculations are important to frame our findings in their appropriate context and we have included these in the text of the manuscript.

*4) The GWAS to viral sequence variation is probably the most interesting finding of this study, with 48 viral amino acids showing significant associations with host SNPs in the MHC. The strongest association is observed for position 135/Nef within an A\*24:04 restricted epitope and for a SNP which is known to tag A\*24:02. Assuming that this effect has a structural basis (i.e., the molecular interaction between peptide and MHC), why only show amino acids in the viral genome? Why not make it more "symmetric" and also look at the individual amino acids in the HLA molecules? Because the authors have imputed amino acid polymorphisms of the HLA proteins (Jia et al.), this should be relatively easy and potentially interesting*.

We now include the analysis proposed by the reviewers. The amino acid association testing is largely consistent with the analysis of classical HLA alleles. It also adds a mechanistic dimension. We have added this analysis to the text and provide full association results online ([http://g2g.labtelenti.org](http://g2g.labtelenti.org/)).

[^1]: These authors contributed equally to this work.

[^2]: Department of Computational Biology and Applied Algorithmics, Max Planck Institute for Informatics, Saarbrücken, Germany.

[^3]: Significant associations (p \< 2.4 × 10^-12^) were observed for 48 HIV-1 amino acid variants. The table shows the major amino acid variants present at each specific HIV-1 position, the strongest associated SNP and its linked HLA class I allele(s), if applicable. The column 'CTL Epitope (codons)' lists published, optimally described CTL epitopes (available at <http://www.hiv.lanl.gov/content/immunology/tables/optimal_ctl_summary.html> and in \[[@bib8]\]) restricted by the tagged HLA class I allele(s) specified, and their positions within the protein. Where multiple overlapping epitopes restricted by the same HLA class I allele have been described, only one is shown. Associations where no relevant CTL epitope has been described are indicated with a dash. The last three columns give association p-values for comparisons between human SNPs and viral amino acids, human SNPs and plasma VL and viral amino acids and plasma VL, respectively. For tests involving viral amino acids accommodating more than 1 alternate allele, the smallest association p-value observed at that position is reported.

[^4]: ACTG = AIDS Clinical Trials Group Network; CARLOS III = Instituto de Salud Carlos III; HOMER = HAART Observational Medical Evaluation and Research Study; IHCS = International HIV Controllers Study; IRSICAIXA = AIDS Research Institute IrsiCaixa; SHCS = Swiss HIV Cohort Study; WAHCS = Western Australian HIV Cohort Study.
